Journal of Leukocyte Biology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published online as doi:10.1189/jlb.0105032 on July 20, 2005

Published online before print July 20, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0105032v1
78/4/1008    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhuang, D.
Right arrow Articles by Dong, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhuang, D.
Right arrow Articles by Dong, F.
(Journal of Leukocyte Biology. 2005;78:1008-1015.)
© 2005 by Society for Leukocyte Biology

Tyrosine 729 of the G-CSF receptor controls the duration of receptor signaling: involvement of SOCS3 and SOCS1

Dazhong Zhuang*, Yaling Qiu*, S. Jaharul Haque{dagger} and Fan Dong*,1

* Department of Biological Sciences, University of Toledo, Ohio; and
{dagger} Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Ohio

1Correspondence: Department of Biological Sciences, University of Toledo, 2801 West Bancroft Street, Toledo, OH 43606. E-mail: fdong{at}utnet.utoledo.edu


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Mutations in the granulocyte-colony stimulating factor receptor (G-CSF-R) gene resulting in carboxy terminal truncation have been associated with acute myeloid leukemia (AML). The truncated G-CSF-R from AML patients mediate enhanced and prolonged activation of signal transducer and activator of transcription 5 (Stat5). It has been shown that Src homology-2 (SH2)-containng tyrosine phosphatase-1 attenuates the intensity of G-CSF-induced Stat5 activation through interacting with the carboxy terminus of the G-CSF-R. Using a series of tyrosine-to-phenylalanine substitution mutants, we show here that tyrosine (Tyr) 729, located in the carboxy terminus of the G-CSF-R, controls the duration of G-CSF-stimulated activation of Stat5, Akt, and extracellular signal-regulated kinase 1/2. It is interesting that activation of these signaling molecules by G-CSF was prolonged by pretreating cells with actinomycin D or cyclohexamide, suggesting that de novo protein synthesis is required for appropriate termination of G-CSF-R signaling. The transcripts for suppressor of cytokine signaling 3 (SOCS3) and SOCS1 were up-regulated rapidly upon G-CSF stimulation. Expression of SOCS3 or SOCS1, but not SOCS2 and cytokine-inducible SH2 domain-containing protein, completely suppressed G-CSF-induced Stat5 activation but had only a weak effect on Stat5 activation mediated by the receptor mutant lacking Tyr 729. SOCS1 and SOCS3 also inhibited G-CSF-dependent cell proliferation, but the inhibitory effect of the two SOCS proteins on cell proliferation was diminished when Tyr 729 of the G-CSF-R was mutated. These data indicate that Tyr 729 of the G-CSF-R is required for SOCS1- and SOCS3-mediated negative regulation of G-CSF-R signaling and that the duration and intensity of G-CSF-induced Stat5 activation are regulated by two distinct mechanisms.

Key Words: cytokines • signal transduction • granulopoiesis


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Granulocyte-colony stimulating factor (G-CSF) is a hematopoietic cytokine, which is critically involved in the regulation of granulopoiesis [1 ]. G-CSF supports the proliferation, differentiation, and survival of myeloid progenitor cells. The G-CSF receptor (G-CSF-R), a member of the cytokine receptor superfamily, mediates the biological actions of G-CSF. Stimulation of cells with G-CSF activates multiple intracellular signal transduction pathways, which are important for the biological activities of G-CSF. These include signal transducers and activators of transcription (Stats), mitogen-activated protein kinase, and phosphatidylinositol-3 kinase/Akt cascades, among others [2 , 3 ]. The G-CSF-R lacks intrinsic kinase activities in the cytoplasmic domain and transduces signals via interacting with intracellular protein kinases such as the Janus tyrosine kinase (Jak) and Src family kinases [2 , 3 ].

G-CSF stimulates the activation of Stat3, Stat5, and to a lesser extent, Stat1. Stat3 was identified as being critical for G-CSF-induced cell proliferation, differentiation, and survival [4 , 5 ], but a recent study using conditional gene ablation in transgenic mice indicated that Stat3 may negatively regulate granulopoiesis [6 ]. Stat5 exists in two major forms, i.e., Stat5a and Stat5b, which are encoded by two closely related genes, and has been shown to positively regulate cell proliferation and granulocytic differentiation induced by G-CSF [7 , 8 ]. Although Stat5a/b-deficient mice were not neutropenic, bone marrow cells from these mice exhibited reduced response to G-CSF stimulation in in vitro colony formation assay [9 ]. Apart from its role in normal granulopoiesis, Stat5 also appears to play a part in leukemogenesis. Expression of leukemogenic proteins such as Bcr-Abl, Tel-Jak2, and FMS-like fetal liver tyrosine kinase 3/internal tandem duplication is associated with constitutive activation of Stat5 [10 11 12 13 ]. Notably, deregulated activation of Stat5 alone can convert interleukin (IL)-3-dependent cells to growth factor independence [14 ].

Mutations in the G-CSF-R gene have been identified in a subgroup of patients with acute myelogenous leukemia (AML) evolving from severe congenital neutropenia (SCN) [15 16 17 18 ]. These mutations, which result in the carboxy terminal truncation of the G-CSF-R, are almost always present in the patients who developed AML after a history of SCN, strongly suggesting that the mutations have a role in leukemogenesis. Expression of the truncated G-CSF-R in hematopoietic cells leads to augmented cell proliferation and survival but defective granulocytic differentiation [15 , 19 ]. Notably, G-CSF-stimulated activation of Stat5 is markedly enhanced and prolonged in these cells [7 , 20 ], indicating that the carboxy terminal region of the G-CSF-R negatively regulates Stat5 activation. It has been shown that Src homology 2 (SH2)-containing protein tyrosine phosphatase-1 (Shp-1) negatively regulates the intensity, but not the duration, of G-CSF-stimulated Stat5 activation [21 ]. The negative effect of Shp-1 on Stat5 activation requires the carboxy terminus of the G-CSF-R, but the tyrosine residues located in the receptor’s carboxy terminus are dispensable for Shp-1 action [21 , 22 ]. In this paper, we show that tyrosine (Tyr) 729 of the G-CSF-R, located in the receptor’s carboxy terminus, controls the duration of G-CSF-stimulated activation of Stat5, Akt, and extracellular signal-regulated kianse 1/2 (Erk1/2). Our data also strongly suggest that suppressor of cytokine signaling (SOCS)1 and SOCS3 are involved in the negative regulation of G-CSF-R signaling, presumably through interacting with Tyr 729 of the G-CSF-R.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cells
Murine 32D and Ba/F3 cells expressing the wild-type (WT) and the D715 form of the human G-CSF-R have been described [19 ]. Cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 10% WEHI-3B cell-conditioned media, 100 U/ml penicillin, and 100 µg/ml streptomycin. 293T cells were maintained in Dulbecco’s modified Eagle’s medium containing 10% FBS supplemented with penicillin and streptomycin.

Reagents
Antibodies against Akt and Erk1/2 and phospho-specific antibodies against Akt, Erk1/2, and Stat5 were purchased from Cell Signaling Technology (Beverly, MA). Anti Stat5 (C-17) antibody was from Santa Cruz Biotechnology (CA). Monoclonal antibody to the G-CSF-R was obtained from BD Biosciences (San Diego, CA). Anti-FLAG (M2) antibody was from Sigma Chemical Co. (St. Louis, MO). [{gamma}-32P]Adenosine 5'-triphosphate (ATP) and an enhanced chemiluminescence (ECL) kit were purchased from PerkinElmer Life and Analytical Sciences (Boston, MA) and Pierce Biotechnology (Rockford, IL), respectively. FuGENE 6 transfection reagent was from Roche Diagnostics (Indianapolis, IN). Fluorophore-labeled goat anti-mouse immunoglobulin G (IgG) antibody (Alexa Fluor® 488) was purchased from Molecular Probes (Eugene, OR).

Stable transfection
The cDNAs encoding the different tyrosine-to-phenylalanine substitution mutants of the G-CSF-R (kindly provided by Dr. Ivo P. Touw, Erasmus University, Rotterdam) were cloned in the pBabe-puro retroviral expression vector as described [23 ]. 32D cells were transfected by electroporation and selected in medium containing puromycin (1 µg/ml), 24 h after transfection. Individual clones were expanded and examined for expression of transfected proteins by Western blotting. Three independent clones were pooled and used in subsequent experiments.

Transient transfection
The expression vectors encoding FLAG-tagged cytokine-inducible SH2-domain-containing protein (CIS), SOCS1, SOCS2, SOCS3, and Stat5a have been described [7 , 24 ]. 293T cells were plated on 24-well plates and transfected with 0.1 µg pBabe G-CSF-R, 0.5 µg pXM-Stat5a, and 0.1 µg SOCS expression vectors using FuGENE 6. In some experiments, higher amounts of SOCS expression vectors were used to see the expression of different SOCS proteins. Twenty hours after transfection, cells were deprived of serum for 4 h and stimulated with G-CSF for the times as indicated. Ba/F3 cells were transiently transfected with 10 µg empty vector or expression constructs for SOCS1 and SOCS3 by electroporation as described previously [25 ].

Western blot analysis
Cells were starved in the absence of serum for 4 h and subsequently stimulated with G-CSF (20 ng/ml) for the times indicated. Cells were washed with ice-cold phosphate-buffered saline and resuspended in lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 10 mM NaF, 0.5 mM dithiothreitol, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and 1 mM vanadate). After incubation on ice for 20 min, lysates were cleared by centrifugation at 12,000 rpm for 20 min at 4°C. Supernatants were collected, and proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis prior to transfer to Immobilon membranes. The membranes were incubated with the appropriate antibodies. Western blots were developed using ECL.

Northern blot analysis
Total RNA was extracted with RNA-BeeTM RNA isolation reagent (Tel-Test Inc., Friendswood, TX). RNA (10 µg) was run on a 1% agarose gel and transferred to a Hybond-N membrane (Amersham Biosciences, Piscataway, NJ). The membrane was prehybridized for 1 h at 42°C in NorthernMaxTM hybridiztion buffer (Ambion, Austin, TX) and hybridized overnight at 42°C after addition of the [{gamma}-32P]-labeled probe. The membrane was washed and developed.

Electrophoretic mobility shift assay (EMSA)
EMSAs were performed as described previously using whole cell extracts [7 ]. The ß-casein probe (5'-AGATTTCTAGGAATTCAAATC-3'), derived from the promoter of the bovine ß-casein gene, was end-labeled using polynucleotide kinase and [{gamma}-32P]ATP.

Flow cytometry
Cells (106) were incubated at 4°C for 30 min sequentially with the anti-G-CSF-R antibody (1 µg/100 µl) and the fluorophore-labeled goat anti-mouse IgG antibody (2 µg/100 µl), with washing between each step. Samples were analyzed by flow cytometry using a FACScan (Becton Dickinson, San Jose, CA).

Cell proliferation assay
Cell proliferation was measured using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS; CellTiter 96® aqueous nonradioactive cell proliferation assay, Promega, Madison, WI). After extensive washing, 2 x 104 cells were incubated in triplicate in 100 µl RPMI-1640 medium in 96-well plates in the presence of G-CSF (20 ng/ml) for 24 h. MTS (10 µl) was added to each well, and the plates were read 2 h later at 490 nm wavelength in a microplate luminometer (Molecular Devices, Sunnyvale, CA).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
It has been shown that truncation of the carboxy terminal region of the G-CSF-R, as seen in some patients with AML/SCN, resulted in enhanced and prolonged Stat5 activation in response to G-CSF [7 ]. This region contains three tyrosine residues, i.e., Tyr 729, Tyr 744, and Tyr 764, which are involved in regulating cell proliferation and differentiation [23 , 26 , 27 ]. To investigate whether the carboxy terminal tyrosine residues have a role in modulating G-CSF-stimulated Stat5 activation, we expressed a series of tyrosine-to-phenylalanine substitution mutants of the G-CSF-R (Fig. 1A ) in murine myeloid 32D cells. Expression of the different G-CSF-R forms was confirmed by flow cytometric analysis (Fig. 1B) . G-CSF-induced activation of Stat5, as determined by its tyrosine phosphorylation, was enhanced significantly and protracted in cells transfected with the D715 mutant lacking the carboxy terminal 98 amino acids (32D/D715), previously shown to be expressed in some patients with AML/SCN (Fig. 2 ). Stat5 activation mediated by the mA mutant, in which the three carboxy terminal tyrosine residues were mutated to phenylalanine, was extended but not augmented. Notably, the D715 and the mA mutants also mediated prolonged (but not enhanced) activation of Akt and Erk1/2. These data indicate that the carboxy terminal tyrosine residues of the G-CSF-R are implicated in regulating the duration of G-CSF-stimulated signaling pathways.



View larger version (39K):
[in this window]
[in a new window]
  		Figure 1. Expression of the different G-CSF-R in 32D cells. (A) Schematic representation of the different forms of the G-CSF-R. Shown are the transmembrane and cytoplasmic domains. Boxes 1–3 denote regions that are conserved among some members of the cytokine receptor superfamily. Cytoplasmic tyrosine residues are also indicated. (B) Flow cytometric analysis of G-CSF-R expression in 32D cells. Cells were incubated sequentially with the anti G-CSF-R antibody and the fluorophore-labeled goat anti-mouse IgG antibody at 4°C. Samples were analyzed by flow cytometry. Ctr, control.

 


View larger version (20K):
[in this window]
[in a new window]
  		Figure 2. Activation of Stat5, Akt, and Erk1/2 by G-CSF in 32D cells expressing the different forms of the G-CSF-R. (A) 32D cells expressing the WT, D715, or mA receptor were starved in serum-free medium for 4 h prior to G-CSF stimulation for 15 min. Phosphorylation (p) of Stat5, Akt, and Erk1/2 was determined by Western blotting using the phospho-specific antibodies. The membranes were reprobed with antibodies to Stat5, Akt, and Erk1/2. (B) Survival of 32D cells upon G-CSF withdrawal. Cells, as indicated, were incubated with G-CSF for 8 h and then cultured in quadruplicate in medium containing no growth factors. Cell viability was determined by exclusion of trypan blue staining at the indicated times. The data are presented as mean ± SD of quadruplicate determinations. *, Significant differences as compared with the survival of 32D/WT cells (Student’s t-test; P<0.05). Comparable results were obtained in four independent experiments.

 
Activation of Stat5, Akt, and Erk1/2 is known to promote cell survival [28 29 30 31 32 ]. Sustained and augmented activation of Stat5 by the D715 mutant has been shown to protect Ba/F3 cells from apoptosis induced by G-CSF withdrawal [7 ]. We compared the survival of 32D cells expressing the different receptor forms upon G-CSF withdrawal. Cells were pulsed with G-CSF for 8 h prior to incubation in medium containing no growth factors. As compared with the WT receptor, the D715 mutant and the mA mutant markedly and moderately, respectively, prolonged the survival of 32D cells (Fig. 2B) . The relative inefficiency of the mA mutant in suppressing apoptosis is likely a result of the fact that unlike the D715 mutant, the mA mutant did not mediate enhanced Stat5 activation. 32D cells expressing the different G-CSF-R forms, which were maintained in IL-3, died at comparable rates upon deprivation of growth factors (data not shown).

To determine which carboxy terminal tyrosine residue(s) of the G-CSF-R are involved in controlling the duration of G-CSF-activated signaling pathways, we compared Stat5 activation by G-CSF in 32D cells expressing the G-CSF-R mutants that contained single or double tyrosine-to-phenylalanine substitutions. Stat5 tyrosine phosphorylation and subsequent activation of its DNA binding activity in response to G-CSF were significantly prolonged when Tyr 729 was mutated to phenylalanine (Fig. 3A and 3B ). In contrast, substitution of Tyr 744 and/or Y764 had no significant effect on Stat5 activation. Mutation of Tyr 729 also significantly prolonged the activation of Akt and Erk1/2 by G-CSF. It appeared that prolongation of Erk1/2 activation by mA and Y729/764F mutants was less significant than that by the Y729F and Y729/744F mutant (Figs. 2A and 3A) , presumably, as Tyr 764 plays an important role in the activation of Erk1/2 by G-CSF [26 , 27 ]. Upon G-CSF withdrawal, 32D cells expressing the Y729F mutant (32D/Y729F) died at a rate almost identical to that of 32D/mA cells (Fig. 2B) . In addition to 32D cells, Stat5 activation was more sustained in Ba/F3 cells expressing the Y729F mutant than in cells expressing the WT G-CSF-R (Fig. 3C) . Together, these data established that Tyr 729 is critical for regulating the duration of G-CSF-activated signaling pathways.



View larger version (48K):
[in this window]
[in a new window]
  		Figure 3. Activation of Stat5, Akt, and Erk1/2 by the different G-CSF-R forms. 32D and Ba/F3 cells expressing the different forms of the G-CSF-R were stimulated with G-CSF after starvation in serum-free medium for 4 h. (A) Activation of Stat5, Akt, and Erk1/2 in 32D cells was examined by immunoblotting with the phospho-specific antibodies as indicated. The membranes were subsequently probed with antibodies to Stat5, Akt, and Erk1/2. (B) Stat5 DNA binding activity in 32D cells was assessed by EMSA using the ß-casein probe. (C) Activation of Stat5 in Ba/F3 cells was determined by immunoblotting with the phospho-specific Stat5 antibody. The membrane was reprobed for Stat5.

 
To investigate the mechanism by which Tyr 729 of the G-CSF-R down-regulates receptor signaling, we first determined whether de novo protein synthesis was required for the negative regulation. To this end, 32D cells expressing the WT G-CSF-R (32D/WT) were pretreated with RNA synthesis inhibitor actinomycin D or protein synthesis inhibitor cyclohexamide prior to G-CSF stimulation. Pretreatment of cells with actinomycin D or cyclohexamide dramatically prolonged the duration of G-CSF-stimulated activation of Stat5, Akt, and Erk1/2 (Fig. 4 ). Actinomycin D and cyclohexamide had no apparent effect on the magnitudes of their activation. These results indicated that de novo protein synthesis is required for prompt attenuation of G-CSF-stimulated signaling pathways.



View larger version (54K):
[in this window]
[in a new window]
  		Figure 4. Effects of actinomycin D and cycloheximide on G-CSF-induced activation of Stat5, Akt, and Erk1/2. After starvation in serum-free medium for 2 h, 32D/WT cells were treated with actinomycin D (5 µg/ml) or cycloheximide (30 µg/ml) for an additional 2 h prior to stimulation with G-CSF. Whole cell extracts were prepared and examined for Stat5 tyrosine phosphorylation and DNA binding activity using the ß-casein probe and for Akt and Erk1/2 phosphorylation. The membranes were reprobed with the antibodies to Stat5, Akt, and Erk1/2.

 
At least three types of inhibitory molecules have been implicated in the negative regulation of cytokine receptor signaling: protein tyrosine phosphatases, the protein inhibitors of activated Stats, and the SOCS proteins [33 ]. In particular, the SOCS family proteins are induced rapidly upon cytokine stimulation [34 ]. The potential involvement of the four well-characterized SOCS family members, i.e., SOCS1, SOCS2, SOCS3, and CIS, in the regulation of G-CSF signaling was investigated by transient expression of these proteins in 293T cells together with the WT G-CSF-R. G-CSF-stimulated Stat5 activation was completely suppressed upon expression of SOCS1 or SOCS3 (Fig. 5 ). The inhibitory effect of SOCS1 and SOCS3 was also seen even when the two SOCS proteins were expressed at barely detectable levels (data not shown). In contrast, expression of CIS or SOCS2 did not inhibit or even potentiated G-CSF-stimulated activation of Stat5. These results indicate that SOCS1 and SOCS3 play a negative role in the regulation of G-CSF signal transduction.



View larger version (29K):
[in this window]
[in a new window]
  		Figure 5. Effects of the different SOCS proteins on G-CSF-induced Stat5 activation. 293T cells were transiently transfected with cDNAs encoding the WT G-CSF-R and Stat5a, together with cDNAs encoding the different FLAG-tagged SOCS proteins or the empty vector. Twenty hours after transfection, cells were starved for 4 h and stimulated with G-CSF for the indicated times. Whole cell extracts were examined by Western blotting (WB) for Stat5 tyrosine phosphorylation (p-Stat5; top panel) and for expression of Stat5 (middle panel) and the different SOCS proteins using the anti-FLAG antibody (bottom panel).

 
Northern blot analysis was then used to determine whether SOCS1 and SOCS3 were induced by G-CSF in 32D cells expressing the different forms of the G-CSF-R. G-CSF treatment of 32D/WT cells resulted in rapid induction of SOCS3 and SOCS1 transcripts (Fig. 6 ). The transcripts for SOCS3 and SOCS1 started to increase as early as 15 min after G-CSF stimulation and reached peak levels by 30 min and 45 min, respectively. Notably, induction of SOCS3 and SOCS1 by G-CSF was somewhat delayed in 32D/D715 and 32D/Y729F cells, and maximal levels were reached at ~45 min for SOCS3 and 60 min for SOCS1, suggesting that Tyr 729 of the G-CSF-R is required for prompt induction of SOCS3 and SOCS1 expression.



View larger version (24K):
[in this window]
[in a new window]
  		Figure 6. Northern blot analysis of SOCS1 and SOCS3 transcripts. (A) 32D cells expressing the WT, D715, and Y729F forms of the G-CSF-R were stimulated with G-CSF for the indicated times following starvation in serum-free medium for 4 h. Total RNA extracted from the cells was electrophoresed in a 1% agarose gel, blotted to membrane, and probed with [{gamma}-32P]-labeled probes for SOCS1 (top panel) and SOCS3 (middle panel). Sample loadings were determined by ethidium bromide staining of 18S rRNA (bottom panel). (B and C) The intensities of the bands for SOCS1 and SOCS3 transcripts were quantitated using a phosphoimager.

 
We further examined whether the carboxy terminal tyrosine residues of the G-CSF-R were required for the negative effect of SOCS1 and SOCS3 on Stat5 activation. 293T cells were transiently transfected with SOCS1 and SOCS3 expression constructs together with the constructs for the WT G-CSF-R or the different mutants containing single tyrosine-to-phenylalanine substitutions. Although SOCS1 and SOCS3 completely blocked Stat5 activation mediated by the WT G-CSF-R or the mutants that contained Y704F, Y744F, or Y764F mutation, the inhibitory effect of SOCS1 and SOCS3 on Stat5 activation was attenuated when Tyr 729 was mutated (Fig. 7 ). These data demonstrate that Tyr 729 of the G-CSF-R is critical for efficient inhibition of G-CSF-stimulated Stat5 activity by SOCS1 and SOCS3.



View larger version (37K):
[in this window]
[in a new window]
  		Figure 7. Requirement of Tyr 729 of the G-CSF-R for SOCS1- and SOCS3-mediated inhibition of Stat5 activation. 293T cells were transiently transfected with Stat5a expression construct and the expression constructs for the WT and the different tyrosine-to-phenylalanine substitution forms of the G-CSF-R together with constructs for SOCS1, SOCS3, or empty vector. G-CSF-induced tyrosine phosphorylation of Stat5 was examined by Western blotting using the phospho-specific anti-Stat5 antibody. Expression of SOCS1 and SOCS3 was determined using the anti-FLAG antibody.

 
The effects of SOCS1 and SOCS3 on G-CSF-stimulated cell proliferation were then examined in Ba/F3 cells expressing the WT G-CSF-R (BaF/WT) or the Y729F mutant (BaF/Y729F). Cells were transiently transfected with the empty vector or the SOCS1 or SOCS3 expression construct. The transfection efficiency, as determined by expression of a cotransfected green fluorescence protein construct, was ~50% (data not shown). Cell proliferation in response to G-CSF was examined by MTS uptake assay. Expression of SOCS1 or SOCS3 inhibited G-CSF-dependent proliferation of BaF/WT cells (Fig. 8 ). It is notable that the inhibitory effect of the two SOCS proteins was significantly weaker in BaF/Y729F cells than in BaF/WT cells, indicating that effective inhibition of G-CSF-dependent cell proliferation by SOCS1 and SOCS3 requires Tyr 729 of the G-CSF-R.



View larger version (12K):
[in this window]
[in a new window]
  		Figure 8. Effects of SOCS1 and SOCS3 on G-CSF-dependent proliferation. BaF/WT and BaF/Y729F cells were transiently transfected with the empty vector (Ctr) or expression constructs for SOCS1 and SOCS3. Six hours after transfection, cells were washed and incubated in triplicate in serum-free medium for 24 h in the presence of G-CSF (20 ng/ml). Cells were then pulsed with MTS for 2 h, and MTS uptake was determined. Data are presented as percentage (mean±SD) of MTS uptake by cells transfected with the empty vector. Comparable results were obtained in three independent experiments. The differences in the rate of inhibition by SOCS1 and SOCS3 are statistically significant between BaF/WT and BaF/Y729F cells (Student’s t-test; P<0.01).

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Carboxy terminal truncation of the G-CSF-R, as seen in patients with AML/SCN, leads to augmented and prolonged activation of Stat5 by G-CSF, suggesting that the carboxy terminus of the G-CSF-R negatively regulates Stat5 activation. It has been shown that Shp-1 reduces the intensity but not the duration of G-CSF-stimulated Stat5 activation, and the carboxy terminal region of the G-CSF-R but not the tyrosine residues located in this region is required for the inhibitory action of Shp-1 [21 ]. In this paper, we have investigated the mechanism by which the carboxy terminus of the G-CSF-R regulates the duration of Stat5 activation. Here, we provide the first evidence that Tyr 729 of the G-CSF-R controls the duration but not the intensity of G-CSF-stimulated Stat5 activation. We also demonstrate that SOCS1 and SOCS3 attenuate G-CSF-R signaling, and Tyr 729 of the G-CSF-R is required for the maximal inhibitory effects of SOCS1 and SOCS3.

Our results are consistent with recent studies showing that SOCS3 binds to Tyr 729 of the G-CSF-R and inhibits Stat-dependent luciferase activity stimulated by G-CSF [35 36 37 ]. However, these studies did not examine Stat5 tyrosine phosphorylation and DNA binding activity in hematopoietic cells, and therefore, it remains unknown as to which aspects of Stat5 activation are affected by SOCS3. The data presented here strongly suggest that SOCS3 and SOCS1 control the duration, but not the magnitude, of Stat5 activation in hematopoietic cells. It appears that Tyr 729 controls the functions of SOCS3 and SOCS1 by at least two distinct mechanisms. Removal of Tyr 729 from the G-CSF-R through carboxy terminal truncation or amino acid substitution not only delays the induction of SOCS3 and SOCS1 transcripts by G-CSF but also diminishes the negative effect of SOCS3 and SOCS1 on Stat5 activation. Thus, Tyr 729 of the G-CSF-R regulates the rates at which SOCS3 and SOCS1 are up-regulated by G-CSF and the efficacies with which the two SOCS proteins inhibit G-CSF-R signaling. Conceivably, mutation of Tyr 729 causes prolonged G-CSF-R signaling by disrupting both negative regulatory mechanisms.

In addition to deregulated Stat5 activation, carboxy terminal truncation of the G-CSF-R results in sustained activation of Akt by G-CSF [38 , 39 ]. Our results indicate that Tyr 729 of the G-CSF-R is critically involved in controlling the duration of G-CSF-stimulated activation of Akt and Erk1/2. Activation of Akt and Erk1/2 by G-CSF was also prolonged upon inhibition of protein or RNA synthesis, suggesting that SOCS1 and SOCS3 may also exert a negative effect on the activation of Akt and Erk1/2. Indeed, expression of SOCS1 or SOCS3 in 293T cells attenuated G-CSF-induced Akt phosphorylation (data not shown). It is likely that SOCS1 and SOCS3 may target a common upstream component of the Stat5, Akt, and Erk1/2 pathways, although one cannot exclude the possibility that the two SOCS proteins may directly inhibit the activation of individual components within the three pathways. As the Jak and Src family kinases are differentially required for G-CSF-stimulated activation of Stat5 and Akt, respectively [38 ], one potential, common target of SOCS1 and SOCS3 is the G-CSF-R. In support of this, we have observed that tyrosine phosphorylation of the G-CSF-R induced by G-CSF was completely blocked upon expression of SOCS1 or SOCS3 in 293T cells (data not shown).

A recent study showed that CIS was also up-regulated by G-CSF and bound to phosphopeptides corresponding to Tyr 729 and Tyr 744 of the G-CSFR [40 ]. However, we consistently observed that expression of CIS enhanced Stat5 activation by G-CSF in 293T cells, consistent with the report by van de Geijn et al. [37 ]. It remains to be determined, with respect to the relative contribution of SOCS1 and SOCS3 to the attenuation of G-CSF-R signaling and the precise mechanism by which the two SOCS proteins down-regulate the activation of G-CSF-stimulated pathways. In addition to Tyr 729, SOCS3 has been shown to bind to Tyr 704 of the G-CSF-R with a reduced affinity [35 ], which may explain the partial inhibitory effect of SOCS3 on Stat5 activation mediated by the Y729F mutant. In contrast to SOCS3, it is generally believed that SOCS1 inhibits cytokine receptor signaling via interacting directly with the Jak family kinases but not with the cytokine receptors [34 , 41 ]. In fact, it has been shown that SOCS1 fails to bind to any of the cytoplasmic tyrosine residues including Tyr 729 of the G-CSF-R [35 ]. We also have been unable to detect any interaction between SOCS1 and the G-CSF-R (unpublished data). However, our data clearly show that Tyr 729 of the G-CSF-R is required for the maximal inhibitory effect of SOCS1 on G-CSF-stimulated Stat5 activation. Whether SOCS1 may interact indirectly with Tyr 729 of the G-CSF-R remains to be examined.

Regardless of the mechanisms whereby SOCS3 and SOCS1 exert their negative effect on G-CSF-R signaling, the results presented here together with the previously report [21 ] demonstrate that the intensity and duration of G-CSF-stimulated Stat5 activation are regulated by at least two distinct regulatory mechanisms, i.e., the one mediated by Shp-1, which reduces the magnitude of Stat5 activation, and the one mediated by SOCS3 and/or SOCS1, which controls the duration of Stat5 activation (Fig. 9 ). To our knowledge, such a regulatory feature has not been reported for other cytokine receptors. Additionally, our data reveal an important molecular mechanism that explains, at least in part, why truncation of the carboxy terminal region of the G-CSF-R leads to prolonged receptor signaling and may thus contribute to leukemogenesis.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 9. A model of negative regulation of G-CSF-stimulated Stat5 activation. The G-CSF-R form dimers or oligomers upon ligand binding. Shp-1 is constitutively expressed in myeloid cells and controls the magnitude of Stat5 activation via interacting with the carboxy terminus of the G-CSF-R. Carboxy terminal tyrosine residues of the receptor appear dispensable for Shp-1 action [21 , 22 ]. SOCS3 and SOCS1 are up-regulated rapidly by signals transduced from the G-CSF-R and control the duration of Stat5 activation. Tyr 729 of the G-CSF-R is required for the maximal inhibitory activities of SOCS3 and SOCS1.

 


   ACKNOWLEDGEMENTS
 
This work was supported in part by Grants RO1CA92172 (F. D.) and RO1GM60533 (S. J. H.) from the National Institutes of Health. We thank I. P. Touw for the G-CSF-R expression constructs and A. Quinn and S. Linkes for assistance with flow cytometry.

Received January 19, 2005; revised June 12, 2005; accepted June 16, 2005.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Demetri, G. D., Griffin, J. D. (1991) Granulocyte colony-stimulating factor and its receptor Blood 78,2791-2808[Free Full Text]
  2. Avalos, B. R. (1996) Molecular analysis of the granulocyte colony-stimulating factor receptor Blood 88,761-777[Free Full Text]
  3. Akbarzadeh, S., Layton, J. E. (2001) Granulocyte colony-stimulating factor receptor: structure and function Vitam. Horm. 63,159-194[Medline]
  4. McLemore, M. L., Grewal, S., Liu, F., Archambault, A., Poursine-Laurent, J., Haug, J., Link, D. C. (2001) STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation Immunity 14,193-204[CrossRef][Medline]
  5. de Koning, J. P., Soede-Bobok, A. A., Ward, A. C., Schelen, A. M., Antonissen, C., van Leeuwen, D., Lowenberg, B., Touw, I. P. (2000) STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1) Oncogene 19,3290-3298[CrossRef][Medline]
  6. Lee, C. K., Raz, R., Gimeno, R., Gertner, R., Wistinghausen, B., Takeshita, K., DePinho, R. A., Levy, D. E. (2002) STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation Immunity 17,63-72[CrossRef][Medline]
  7. Dong, F., Liu, X., de Koning, J. P., Touw, I. P., Hennighausen, L., Larner, A., Grimley, P. M. (1998) Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor J. Immunol. 161,6503-6509[Abstract/Free Full Text]
  8. Ilaria, R. L. J., Hawley, R. G., Van Etten, R. A. (1999) Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation Blood 93,4154-4166[Abstract/Free Full Text]
  9. Teglund, S., McKay, C., Schuetz, E., van Deursen, J. M., Stravopodis, D., Wang, D., Brown, M., Bodner, S., Grosveld, G., Ihle, J. N. (1998) Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses Cell 93,841-850[CrossRef][Medline]
  10. Ilaria, R. L. J., Van Etten, R. A. (1996) P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members J. Biol. Chem. 271,31704-31710[Abstract/Free Full Text]
  11. Sillaber, C., Gesbert, F., Frank, D. A., Sattler, M., Griffin, J. D. (2000) STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells Blood 95,2118-2125[Abstract/Free Full Text]
  12. Ho, J. M., Beattie, B. K., Squire, J. A., Frank, D. A., Barber, D. L. (1999) Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling Blood 93,4354-4364[Abstract/Free Full Text]
  13. Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Muller, C., Gruning, W., Kratz-Albers, K., Serve, S., Steur, C., Buchner, T., Kienast, J., Kanakura, Y., Berdel, W. E., Serve, H. (2000) Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways Blood 96,3907-3914[Abstract/Free Full Text]
  14. Onishi, M., Nosaka, T., Misawa, K., Mui, A. L., Gorman, D., McMahon, M., Miyajima, A., Kitamura, T. (1998) Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation Mol. Cell. Biol. 18,3871-3879[Abstract/Free Full Text]
  15. Dong, F., Brynes, R. K., Tidow, N., Welte, K., Lowenberg, B., Touw, I. P. (1995) Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia N. Engl. J. Med. 333,487-493[Abstract/Free Full Text]
  16. Dong, F., Dale, D. C., Bonilla, M. A., Freedman, M., Fasth, A., Neijens, H. J., Palmblad, J., Briars, G. L., Carlsson, G., Veerman, A. J., Welte, K., Lowenberg, B., Touw, I. P. (1997) Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia Leukemia 11,120-125[CrossRef][Medline]
  17. Tidow, N., Pilz, C., Teichmann, B., Muller-Brechlin, A., Germeshausen, M., Kasper, B., Rauprich, P., Sykora, K. W., Welte, K. (1997) Clinical relevance of point mutations in the cytoplasmic domain of the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia Blood 89,2369-2375[Abstract/Free Full Text]
  18. Aprikyan, A. A., Kutyavin, T., Stein, S., Aprikian, P., Rodger, E., Liles, W. C., Boxer, L. A., Dale, D. C. (2003) Cellular and molecular abnormalities in severe congenital neutropenia Exp. Hematol. 31,372-381[CrossRef][Medline]
  19. Dong, F., van Buitenen, C., Pouwels, K., Hoefsloot, L. H., Lowenberg, B., Touw, I. P. (1993) Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation Mol. Cell. Biol. 13,7774-7781[Abstract/Free Full Text]
  20. Hermans, M. H., Antonissen, C., Ward, A. C., Mayen, A. E., Ploemacher, R. E., Touw, I. P. (1999) Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia-derived mutation in the G-CSF receptor gene J. Exp. Med. 189,683-692[Abstract/Free Full Text]
  21. Dong, F., Qiu, Y., Yi, T., Touw, I. P., Larner, A. C. (2001) The carboxyl terminus of the granulocyte colony-stimulating factor receptor, truncated in patients with severe congenital neutropenia/acute myeloid leukemia, is required for SH2-containing phosphatase-1 suppression of Stat activation J. Immunol. 167,6447-6452[Abstract/Free Full Text]
  22. Ward, A. C., Oomen, S. P., Smith, L., Gits, J., van Leeuwen, D., Soede-Bobok, A. A., Erpelinck-Verschueren, C. A., Yi, T., Touw, I. P. (2000) The SH2 domain-containing protein tyrosine phosphatase SHP-1 is induced by granulocyte colony-stimulating factor (G-CSF) and modulates signaling from the G-CSF receptor Leukemia 14,1284-1291[CrossRef][Medline]
  23. de Koning, J. P., Soede-Bobok, A. A., Schelen, A. M., Smith, L., van Leeuwen, D., Santini, V., Burgering, B. M., Bos, J. L., Lowenberg, B., Touw, I. P. (1998) Proliferation signaling and activation of Shc, p21Ras, and Myc via tyrosine 764 of human granulocyte colony-stimulating factor receptor Blood 91,1924-1933[Abstract/Free Full Text]
  24. Haque, S. J., Harbor, P. C., Williams, B. R. (2000) Identification of critical residues required for suppressor of cytokine signaling-specific regulation of interleukin-4 signaling J. Biol. Chem. 275,26500-26506[Abstract/Free Full Text]
  25. Dong, F., Gutkind, J. S., Larner, A. C. (2001) Granulocyte colony-stimulating factor induces ERK5 activation, which is differentially regulated by protein-tyrosine kinases and protein kinase C. Regulation of cell proliferation and survival J. Biol. Chem. 276,10811-10816[Abstract/Free Full Text]
  26. de Koning, J. P., Schelen, A. M., Dong, F., van Buitenen, C., Burgering, B. M., Bos, J. L., Lowenberg, B., Touw, I. P. (1996) Specific involvement of tyrosine 764 of human granulocyte colony-stimulating factor receptor in signal transduction mediated by p145/Shc/GRB2 or p90/GRB2 complexes Blood 87,132-140[Abstract/Free Full Text]
  27. Akbarzadeh, S., Ward, A. C., McPhee, D. O., Alexander, W. S., Lieschke, G. J., Layton, J. E. (2002) Tyrosine residues of the granulocyte colony-stimulating factor receptor transmit proliferation and differentiation signals in murine bone marrow cells Blood 99,879-887[Abstract/Free Full Text]
  28. Smithgall, T. E., Briggs, S. D., Schreiner, S., Lerner, E. C., Cheng, H., Wilson, M. B. (2000) Control of myeloid differentiation and survival by Stats Oncogene 19,2612-2618[CrossRef][Medline]
  29. Battle, T. E., Frank, D. A. (2002) The role of STATs in apoptosis Curr. Mol. Med. 2,381-392[CrossRef][Medline]
  30. Datta, S. R., Brunet, A., Greenberg, M. E. (1999) Cellular survival: a play in three Akts Genes Dev. 13,2905-2927[Free Full Text]
  31. Vivanco, I., Sawyers, C. L. (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat. Rev. Cancer 2,489-501[CrossRef][Medline]
  32. Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A., Greenberg, M. E. (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms Science 286,1358-1362[Abstract/Free Full Text]
  33. Hilton, D. J. (1999) Negative regulators of cytokine signal transduction Cell. Mol. Life Sci. 55,1568-1577[CrossRef][Medline]
  34. Krebs, D. L., Hilton, D. J. (2001) SOCS proteins: negative regulators of cytokine signaling Stem Cells 19,378-387[Abstract/Free Full Text]
  35. Hortner, M., Nielsch, U., Mayr, L. M., Johnston, J. A., Heinrich, P. C., Haan, S. (2002) Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction J. Immunol. 169,1219-1227[Abstract/Free Full Text]
  36. van de Geijn, G. J., Gits, J., Aarts, L. H., Heijmans-Antonissen, C., Touw, I. P. (2004) G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact Blood 104,667-674[Abstract/Free Full Text]
  37. van de Geijn, G. J., Gits, J., Touw, I. P. (2004) Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling J. Leukoc. Biol. 76,237-244[Abstract/Free Full Text]
  38. Dong, F., Larner, A. C. (2000) Activation of Akt kinase by granulocyte colony-stimulating factor (G-CSF): evidence for the role of a tyrosine kinase activity distinct from the Janus kinases Blood 95,1656-1662[Abstract/Free Full Text]
  39. Hunter, M. G., Avalos, B. R. (2000) Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival Blood 95,2132-2137[Abstract/Free Full Text]
  40. Hunter, M. G., Jacob, A., O’Donnell, L. C., Agler, A., Druhan, L. J., Coggeshall, K. M., Avalos, B. R. (2004) Loss of SHIP and CIS recruitment to the granulocyte colony-stimulating factor receptor contribute to hyperproliferative responses in severe congenital neutropenia/acute myelogenous leukemia J. Immunol. 173,5036-5045[Abstract/Free Full Text]
  41. Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., Ohtsuka, S., Imaizumi, T., Matsuda, T., Ihle, J. N., Yoshimura, A. (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop EMBO J. 18,1309-1320[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
K. Jiang, N. Hein, K. Eckert, J. Luscher-Firzlaff, and B. Luscher
Regulation of the MAD1 promoter by G-CSF
Nucleic Acids Res., March 1, 2008; 36(5): 1517 - 1531.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Zhuang, Y. Qiu, S. C. Kogan, and F. Dong
Increased CCAAT Enhancer-binding Protein {epsilon} (C/EBP{epsilon}) Expression and Premature Apoptosis in Myeloid Cells Expressing Gfi-1 N382S Mutant Associated with Severe Congenital Neutropenia
J. Biol. Chem., April 21, 2006; 281(16): 10745 - 10751.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0105032v1
78/4/1008    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhuang, D.
Right arrow Articles by Dong, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhuang, D.
Right arrow Articles by Dong, F.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS